Scope for Gene therapy.

Epidermolysis bullosa (EB) is a rare and genetically determined skin fragility disorders. It has many genetic and symptomatic variations, but all share the prominent symptom of extremely fragile skin that blisters and tears from minor friction to trauma. It is always painful, often pervasive and debilitating. Its affects 1 out of every 50,000 live births and those born with it are often called ‘Butterfly Children’ that is delicate and fragile as butterfly wings. As there is no standard protocol for the treatment of EB and clinic features remains multiple and varied, hence treatment for the disease remains a major challenge. Therefore the current therapy focuses on prevention of progression of disease, nutritional support, bandage dressing and psychological support to the parents/guardians. Hence the platform provides this is a scope for discovery and development new drugs/treatment strategic plans for the treatment of Eidermolysis bullosa in order to recede the innocent babies’ agony.